Jianyong Chen Selected Research

apogossypolone

4/2010	Preclinical studies of apogossypolone, a novel pan inhibitor of bcl-2 and mcl-1, synergistically potentiates cytotoxic effect of gemcitabine in pancreatic cancer cells.
9/2008	Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo.
2/2008	Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jianyong Chen Research Topics

Disease

17	Neoplasms (Cancer) 07/2022 - 01/2005
4	Lymphoma (Lymphomas) 01/2020 - 01/2005
2	Carcinoma (Carcinomatosis) 05/2021 - 11/2010
2	Tuberculosis (Tuberculoses) 01/2021 - 01/2020
2	Hypothermia 06/2011 - 08/2007
2	Pancreatic Neoplasms (Pancreatic Cancer) 04/2010 - 11/2005
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 09/2008 - 01/2005
2	Squamous Cell Carcinoma of Head and Neck 03/2006 - 07/2005
1	Polycystic liver disease 01/2022
1	COVID-19 01/2022
1	Deafness (Deaf Mutism) 01/2022
1	Portal Hypertension 01/2022
1	Liver Diseases (Liver Disease) 01/2022
1	Precocious Puberty 01/2022
1	Varicose Veins (Varicose Vein) 01/2022
1	Autosomal Dominant Polycystic Kidney (ADPKD) 01/2022
1	Facial Nerve Injuries 01/2022
1	Vertigo (Positional Vertigo) 11/2021
1	Fibrosis (Cirrhosis) 10/2017
1	Endotoxemia 10/2017
1	Tinnitus 04/2016
1	Stomach Neoplasms (Stomach Cancer) 03/2015
1	Disruptive, Impulse Control, and Conduct Disorders (Kleptomania) 01/2012
1	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 04/2010
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 07/2008
1	Lung Neoplasms (Lung Cancer) 07/2008
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 02/2008
1	Glioblastoma (Glioblastoma Multiforme) 03/2007

Drug/Important Bio-Agent (IBA)

8	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2005
6	GossypolIBA 09/2008 - 01/2005
4	DNA (Deoxyribonucleic Acid)IBA 11/2010 - 11/2005
3	ErbB Receptors (EGF Receptor)IBA 07/2022 - 07/2006
3	apogossypoloneIBA 04/2010 - 02/2008
2	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 12/2019 - 11/2019
2	Pramipexole (Mirapex)FDA LinkGeneric 01/2012 - 06/2011
2	Phosphotransferases (Kinase)IBA 11/2010 - 02/2006
2	lysyl- arginyl- alanyl- lysyl- alanyl- lysyl- threonyl- threonyl- lysyl- lysyl- arginine (PKCS)IBA 11/2010 - 07/2008
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 07/2008 - 07/2006
2	PolyphenolsIBA 03/2006 - 02/2005
1	Drug CombinationsIBA 07/2022
1	Tetrazolium SaltsIBA 07/2022
1	Tyrosine Kinase InhibitorsIBA 07/2022
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 07/2022
1	trametinibIBA 07/2022
1	Paclitaxel (Taxol)FDA LinkGeneric 07/2022
1	Aldehyde DehydrogenaseIBA 07/2022
1	Carboplatin (JM8)FDA LinkGeneric 07/2022
1	osimertinibIBA 07/2022
1	MitogensIBA 07/2022
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 07/2022
1	Capsules (Microcapsules)IBA 01/2022
1	1-dodecylpyridoxal (PLD)IBA 01/2022
1	clonidine-displacing substance (ClDS)IBA 01/2022
1	Connexin 26IBA 01/2022
1	Tamoxifen FDA LinkGeneric 01/2022
1	GhrelinIBA 01/2022
1	Trastuzumab (Herceptin)FDA Link 05/2021
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 05/2021
1	Docetaxel (Taxotere)FDA Link 05/2021
1	Anaplastic Lymphoma KinaseIBA 11/2020
1	AntiportersIBA 01/2020
1	3' Untranslated Regions (3' UTR)IBA 01/2020
1	Glutamic Acid (Glutamate)FDA Link 01/2020
1	Cysteine (L-Cysteine)FDA Link 01/2020
1	Messenger RNA (mRNA)IBA 01/2020
1	MicroRNAs (MicroRNA)IBA 01/2020
1	Transcription Factors (Transcription Factor)IBA 12/2019
1	Carbon Tetrachloride (Tetrachloromethane)IBA 10/2017
1	mosaprideIBA 10/2017
1	SalicylatesIBA 04/2016
1	Pharmaceutical PreparationsIBA 04/2016
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2015
1	Vascular Endothelial Growth Factor DIBA 03/2015
1	2- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- oneIBA 03/2015
1	Sirolimus (Rapamycin)FDA Link 03/2015
1	Vascular Endothelial Growth Factor CIBA 03/2015
1	Cocaine (Cocaine HCl)IBA 06/2011
1	Epidermal Growth Factor (EGF)IBA 11/2010
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 11/2010
1	EnzymesIBA 04/2010
1	Histones (Histone)IBA 04/2010
1	ImmunosorbentsIBA 04/2010
1	Gemcitabine FDA Link 04/2010
1	DNA-Activated Protein KinaseIBA 07/2008
1	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 07/2008
1	MI-219IBA 03/2008
1	U 95666EIBA 08/2007
1	Dopamine (Intropin)FDA LinkGeneric 08/2007
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 03/2007
1	ellipticineIBA 03/2007
1	X-Linked Inhibitor of Apoptosis ProteinIBA 11/2006

Therapy/Procedure

7	Therapeutics 07/2022 - 01/2005
4	Drug Therapy (Chemotherapy) 05/2021 - 01/2005
3	Oral Administration 10/2021 - 01/2020
1	Aftercare (After-Treatment) 11/2021
1	Neoadjuvant Therapy 05/2021
1	Duration of Therapy 01/2021
1	Subcutaneous Injections 10/2017
1	Injections 09/2008
1	Induced Hypothermia 08/2007